GeminIQ Website Logo

Viewing APTOF free

Subscribe for full history, 50+ metrics, screener, watchlist...

Aptose Biosciences Inc.

APTOF

Companies in Biological Products, (No Diagnostic Substances)

Aptose Biosciences Inc. (APTOF) — SEC Financial Statements & Analysis

Aptose Biosciences Inc. (APTOF) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Cash And Cash Equivalents At Carrying Value
-111568879168
Short Term Investments
--------2-215
Restricted Cash And Cash Equivalents At Carrying V…
-31--1------
Restricted Cash Equivalents Current
-3-1-1---0--
Assets Current
Assets Current
6643710101012122025
Cash
1-----------
Restricted Cash
3-----------
Prepaid Expense Current
222222112222
Other Assets Current
000001111100
Property Plant And Equipment Net
000000000000
Assets Noncurrent
Assets Noncurrent
543201111111
Operating Lease Right Of Use Asset
000001111111
Other Assets Noncurrent
4322-0------
Assets
111066710111113132127
Accounts Payable Current
431321272334
Liabilities Current
Accrued Liabilities Current
765533859998
Liabilities Current
1197964101312151212
Operating Lease Liability Current
000000000000
Liabilities Noncurrent
Liabilities Noncurrent
3428191191010--1--
Operating Lease Liability Noncurrent
-00000001111
Liabilities
453726201515201313161313
Common Stock Value
460460460460460457452452450445444439
Additional Paid In Capital
848484848483828279727271
Stockholders Equity
Stockholders Equity
-35-27-19-14-7-5-9-20-3814
Accumulated Other Comprehensive Income Loss Net Of…
-4-4-4-4-4-4-4-4-4-4-4-4
Retained Earnings Accumulated Deficit
-574-566-559-554-547-541-539-532-525-516-504-492
Liabilities And Stockholders Equity
111066710111113132127
Common Stock No Par Value
000000000000
Common Stock Shares Issued
202020202020201816000
Shares Outstanding
333332221111

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-7.65%-----------
20253.03%-50.71%0.61%-4.84%-12.90%7.26%13.76%8.04%17.98%2.64%2.28%-6.36%
2024-25.20%-39.69%-60.24%-26.85%-26.99%-30.16%-50.14%-39.61%-54.98%-40.66%-49.40%-44.88%
2023---1.00%-30.00%-20.50%-17.90%-21.60%-38.89%-23.06%-26.25%-44.37%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
0.55
0.69
0.53
0.36
1.10
2.14
1.05
0.80
0.97
0.78
1.59
2.11
Quick Ratio
0.38
0.46
0.25
0.16
0.79
1.63
0.96
0.70
0.82
0.65
1.45
1.96
Working Capital
-5.08M
-2.86M
-3.30M
-5.73M
651.00K
5.07M
477.00K
-2.55M
-318.00K
-3.38M
7.29M
13.29M
Leverage & Debt
Debt to Equity
-1.31
-1.37
-1.33
-1.39
-2.01
-3.23
-2.20
-6.03
92.40
-5.48
1.68
0.93
Interest Coverage TTM
-84.59
-61.73
-46.52
-101.66
-112.98
-113.52
-159.41
-189.29
-390.84
-
-
-
Debt Ratio
4.23
3.71
4.07
3.57
1.99
1.45
1.84
1.20
0.99
1.22
0.63
0.48
Efficiency & Turnover
Asset Turnover TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Per Share Metrics
Diluted EPS TTM
-10.80
-10.41
-7.56
-8.28
-10.03
-12.13
-19.45
-24.05
-35.92
-37.91
-36.65
-36.89
Free Cash Flow Per Share TTM
-9.81
-8.99
-9.48
-10.65
-12.70
-17.16
-20.19
-22.30
-34.35
-33.05
-32.78
-31.39
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Growth Metrics
Net Income Growth (1Y)
29.18%
0.15%
-46.11%
-47.58%
-54.78%
-50.34%
-27.31%
-15.32%
7.16%
22.44%
-12.28%
-17.54%
EPS Growth (1Y)
7.62%
-14.19%
-61.13%
-65.59%
-72.07%
-68.01%
-46.94%
-34.81%
4.19%
15.34%
-16.90%
-18.65%
Calculated Values
Free Cash Flow TTM
-25.04M
-21.99M
-24.21M
-27.17M
-27.01M
-35.98M
-37.17M
-37.36M
-45.11M
-44.65M
-44.05M
-40.49M
Net Debt
-1.02M
-935.00K
-613.00K
-553.00K
-4.74M
-6.15M
-7.96M
-8.33M
-7.35M
-9.25M
-15.72M
-8.40M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2024-11-25Purchase
Owner: Rice, William G.
Title: Chair, President & CEO
Shares: 100,000
Price/Share: $0.20
Value: $20,000.00
Shares Owned: 613,252
Relationship: Director,Officer
Ownership: Direct
2023-09-22Purchase
Owner: Seizinger, Bernd R.
Title: -
Shares: 17,000
Price/Share: $3.14
Value: $53,380.00
Shares Owned: 17,000
Relationship: Director
Ownership: Direct
2022-09-19Purchase
Owner: Rice, William G.
Title: Chair, President & CEO
Shares: 10,000
Price/Share: $0.68
Value: $6,800.00
Shares Owned: 363,252
Relationship: Director,Officer
Ownership: Direct
2022-09-19Purchase
Owner: Payne, Fletcher
Title: SR VP & Chief Fin. Officer
Shares: 10,000
Price/Share: $0.68
Value: $6,800.00
Shares Owned: 10,000
Relationship: Officer
Ownership: Indirect
2022-06-06Purchase
Owner: Rice, William G.
Title: Chair, President & CEO
Shares: 10,000
Price/Share: $0.97
Value: $9,700.00
Shares Owned: 353,252
Relationship: Director,Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
0.94%
Inst. Shares: 23,979
Shares Outstanding: 2,552,429
2025-12-31
0.98%
Inst. Shares: 23,979
Shares Outstanding: 2,447,353
2025-09-30
0.94%
Inst. Shares: 23,969
Shares Outstanding: 2,552,429
2025-06-30
0.94%
Inst. Shares: 23,991
Shares Outstanding: 2,552,429
2025-03-31
7.27%
Inst. Shares: 154,566
Shares Outstanding: 2,126,287

Research Faster.
Invest Smarter.

Aptose Biosciences Inc. (APTOF) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.